Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.

Robert Weingold,Bernard Zinman,Michaela Mattheus,Anne Pernille Ofstad,Dominik Steubl,Christoph Wanner,Silvio E Inzucchi

Journal of diabetes and its complications（2023）

引用 0|浏览5

暂无评分

摘要

T2D is a well-established risk factor for development and progression of CKD. KDIGO recommends categorization of risk by likelihood of progression to ESKD. Compared to placebo, empagliflozin decreases likelihood of worsening (OR 0.70, 95 % CI 0.62-0.78) and increases likelihood of improvement (OR 1.56, 95 % CI 1.30-1.86) in KDIGO risk category.

查看译文

关键词

Empagliflozin, SGLT2 inhibitor, T2D, Diabetes treatment, Diabetes complications, KDIGO

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要